对于阿尔茨海默氏症疾病的卡尼丁棕基转移酶2级联假设
Hiskias G Keizer1,2, Ruud Brands1,2,3, Ronald S Oosting1,2
1Alloksys Biotechnology, Wageningen, The Netherlands.
Journal of Alzheimer's disease : JAD
|December 25, 2023
概括
这项研究确定了卡尼丁棕基转移酶-2 (CPT2) 作为阿尔茨海默病 (AD) 病因学的关键标. 氧化应激抑制CPT2,可能解释AD的发展,并提供新的治疗途径.
科学领域:
- 生物化学 生物化学
- 神经科学是一个神经科学.
- 线粒体生物学 线粒体生物学
背景情况:
- 尽管进行了广泛的研究,但阿尔茨海默病 (AD) 的确切原因仍未知.
- 主要的AD风险因素汇聚在内部线粒体膜产生过多的过氧化.
研究的目的:
- 建议卡尼丁棕基转移酶-2 (CPT2) 作为阿尔茨海默氏病 (AD) 病因学的中心目标.
- 阐明CPT2抑制有助于AD病变的机制.
主要方法:
- 对CPT2在线粒体β氧化中的作用的假设驱动分析.
- 检查CPT2对过氧化的敏感性.
- CPT2抑制与AD风险因素和疾病表型的相关性.
主要成果:
- CPT2是一种内线粒体膜酶,对脂肪酸β-氧化至关重要,对过氧化非常敏感.
- 由AD风险因素产生的过量的过氧化抑制了CPT2活动.
- 抑制CPT2导致阿尔茨海默病中观察到的特征性病理特征.
结论:
- 在阿尔茨海默病的病因学中,CPT2被确定为一个关键酶.
- 氧化应激诱导的CPT2抑制提供了AD病变发生的统一机制.
- 这种理解为开发针对CPT2.2的新型AD疗法提供了直接的可能性.
相关概念视频
Alzheimer's Disease: Overview
492
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
492
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Allosteric Proteins-ATCase
5.7K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K


